Toboroz
ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole
2025-524995-53-00· 4. fázis· UZ Brussel· Forrás
Toboroz
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
NCT07753148· 1. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· 3. fázis· Takeda· Forrás
Toboroz
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
NCT07656415· 3. fázis· Agios Pharmaceuticals, Inc.· Forrás
Toboroz
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· 3. fázis· PureTech· Forrás
Toboroz
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
2025-521590-13-00· 3. fázis· Janssen Cilag International· Forrás
Toboroz
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095· 1. fázis· Amgen· Forrás
Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
NCT06831955· 2. fázis· Universitaire Ziekenhuizen KU Leuven· Forrás
Contact: Kevin Punie, MD
Még nem toboroz
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
2025-521908-22-00· 2/3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Toboroz
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás
Toboroz
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558· 1. fázis· AstraZeneca· Forrás
Toboroz
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)
2024-511392-15-00· 3. fázis· WSG Women's Cancer Study Group GmbH· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· 3. fázis· AstraZeneca· Forrás
Toboroz
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Fut, nem toboroz
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors
NCT06660654· 2. fázis· Daiichi Sankyo Inc.· Forrás
Toboroz
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990· 2/3. fázis· Bicara Therapeutics· Forrás
Toboroz
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414· 3. fázis· Ascentage Pharma Group Inc.· Forrás
Fut, nem toboroz
Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections
NCT04779970· 2. fázis· Antwerp University Hospital· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
2023-504022-19-01· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· 3. fázis· UNICANCER· Forrás
Toboroz
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
2023-508435-31-00· 1. fázis· Onkure Inc.· Forrás
Fut, nem toboroz
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients with Breast Cancer
NCT06112379· 3. fázis· Astrazeneca AB· Forrás
Toboroz
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
NCT05791409· 1/2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
NCT06113913· 4. fázis· Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW· Forrás
Toboroz
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
NCT06365788· 2. fázis· Universitaire Ziekenhuizen KU Leuven· Forrás
Toboroz
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre, open-label, randomised pragmatic clinical trial
2023-506703-26-00· 3. fázis· Institut Jules Bordet· Forrás
Toboroz
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911· 3. fázis· Ascentage Pharma Group Inc.· Forrás
Toboroz
Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis
NCT06003283· 4. fázis· Universitaire Ziekenhuizen KU Leuven· Forrás
Fut, nem toboroz
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial
2022-501551-90-00· 2/3. fázis· Ziekenhuis Aan De Stroom· Forrás
Fut, nem toboroz
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738· 3. fázis· Olema Pharmaceuticals, Inc.· Forrás
Toboroz
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535· 3. fázis· United Therapeutics· Forrás
Toboroz
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer
NCT05900206· 2. fázis· Karolinska University Hospital· Forrás
Showing 50 of 71.